Ocugen Inc Stock Price, News & Analysis

Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has scheduled a conference call and live webcast for Friday, May 9, 2025, at 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and provide business updates.

The company will release its earnings announcement before the market opens on May 9. Investors can join via phone using U.S. dial-in (800) 715-9871 or international dial-in (646) 307-1963 with Conference ID 1773288. A webcast will be available on Ocugen's investor site, with a replay accessible for approximately 45 days after the event.

Ocugen announced upcoming presentations of its modifier gene therapy platform at two major ophthalmology events: The ARVO 2025 Annual Meeting in Salt Lake City (May 4-8) and Retina World Congress in Ft. Lauderdale (May 8-11). The company will showcase three key therapies:

• OCU400 for retinitis pigmentosa (Phase 3 LiMeliGhT trial)
• OCU410ST for Stargardt disease (Phase 2/3 pivotal trial)
• OCU410 for geographic atrophy (Phase 2 ArMaDa trial)

CEO Dr. Shankar Musunuri confirmed plans to file three Biologics License Applications/Marketing Authorization Applications within three years. The presentations include clinical trial updates, safety data, and efficacy results across multiple sessions. Dr. Huma Qamar, Chief Medical Officer, will lead the company showcase at Eyecelerator and participate in panel discussions at both events.

Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced its participation in the 2025 Cell & Gene Meeting on the Mediterranean in Rome, Italy from April 15-17, 2025.

Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on the panel 'Commercializing ATMPs: Moving from Innovation to Market Success' on April 15 at 10:45 a.m. CEST. The presentation will highlight Ocugen's modifier gene therapy platform and its potential to offer one-time treatments for major blindness diseases.

The company's gene therapy portfolio includes:

• OCU400 for retinitis pigmentosa
• OCU410ST for Stargardt disease
• OCU410 for geographic atrophy

Ocugen (NASDAQ: OCGN) announced positive safety data from the first cohort of its Phase 1 clinical trial for OCU200, a novel fusion protein designed to treat diabetic macular edema (DME). The Data and Safety Monitoring Board (DSMB) has approved proceeding with the second cohort after reviewing safety data from the initial group.

The trial is structured as a multicenter, open-label, dose-escalation study across three cohorts: low dose (0.025 mg), medium dose (0.05 mg), and high dose (0.1 mg). Patients receive two intravitreal injections six weeks apart with a 6-month follow-up period. No serious adverse events related to OCU200 have been reported.

OCU200, combining tumstatin and transferrin proteins, targets approximately 12 million people in the US and 130 million worldwide affected by DME, diabetic retinopathy (DR), and wet age-related macular degeneration. The company aims to complete the Phase 1 trial in H2 2025, particularly addressing the 30-40% of DME patients who don't respond to current anti-VEGF therapies.